Skip to main content

Table 1 (abstract P37). Pregnancy outcomes under canakinumab

From: Abstracts from the ISSAID 2021 Periodic Congress

  Age at pregnancy Last cana dose before conception Doses and duration of cana after conception Date and type of delivery Birth weight APGAR score Fetoplacental anomaly, IUGR, or developmental delay Feeding Current age of the child
1* 25 years 150 mg, 2 weeks 150 mg at 6 and 14 weeks 16 week, miscarriage - - No phenotypic or chromosomal anomaly - -
2* 26 years 150 mg, 14 weeks 150 mg at 31 weeks and 4-to-6-weekly thereafter 37 week, C/S 2.9 kg 8,9,10 No anomaly, IUGR, or delay Breastfed 16 months 2.5 years
3 28 years 150 mg, 4 weeks 150 mg 8-weekly throughout pregnancy 39 week, C/S 3.4 kg 9,10,10 No anomaly, IUGR, or delay Breastfed 8 months 2 years
  1. cana, canakinumab; C/S, Caesarean section; IUGR, intrauterine growth retardation. * the same patient